NEW YORK, Feb. 12, 2026 — Hoth Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its novel exon-skipping therapy targeting allergic diseases. The patent, titled “Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases,” covers a dual-mechanism RNA-based therapeutic strategy designed to modulate upstream immune signaling pathways. The intellectual property milestone strengthens Hoth’s immunology pipeline and reinforces its position in next-generation gene-modulating allergy therapeutics.
Science Significance
The scientific innovation centers on exon-skipping technology applied to immune receptor modulation, a novel approach within allergic disease treatment. The therapy targets FC-Epsilon-RI-Beta, a critical component of the high-affinity IgE receptor complex responsible for mast cell activation and hypersensitivity cascades. By skipping specific exons during mRNA processing, the therapy aims to reduce receptor expression and dampen allergic signaling at its origin. Concurrent modulation of MS4A6A — a gene linked to inflammatory signaling regulation — introduces a synergistic mechanism to further suppress immune overactivation. Targeting upstream molecular drivers rather than downstream symptoms represents a paradigm shift in allergy immunotherapy design.
Regulatory Significance
From a regulatory and compliance perspective, the Notice of Allowance signals that all patent claims have been accepted, moving the therapy toward formal U.S. patent issuance. Intellectual property protection is foundational to regulatory lifecycle strategy, supporting market exclusivity, licensing leverage, and future biologics regulatory filings. As an RNA-based exon-skipping therapy, the candidate will require comprehensive GLP toxicology studies, CMC validation, and phased clinical trials under GCP frameworks. Regulatory agencies will evaluate delivery systems, immunogenicity risk, off-target effects, and long-term safety monitoring before potential approval pathways are established.
Business Significance
Advertisement
Strategically, the patent allowance expands Hoth’s proprietary immunology platform and strengthens its competitive differentiation in inflammatory disease therapeutics. Layered IP protection enhances partnership opportunities, licensing negotiations, and investor confidence. RNA therapeutics represent one of the fastest-growing pharmaceutical innovation segments, with applications spanning rare diseases, oncology, and immunology. Securing foundational patents around mechanistic targets positions Hoth to capture long-term value in the global allergy treatment market.
Patients’ Significance
For patients living with allergic and hypersensitivity disorders, treatment options often focus on symptom suppression rather than disease modification. Antihistamines, corticosteroids, and biologics may reduce inflammation but do not address root immune signaling dysfunction. Exon-skipping therapeutics offer the possibility of precision immune pathway correction, potentially reducing disease severity, frequency of flare-ups, and reliance on chronic medications. Mechanistically targeted RNA therapies could transform long-term management of allergic diseases by intervening at the genetic signaling level.
Policy Significance
The advancement of gene-modulating therapies raises important policy considerations around pricing, reimbursement, and access to precision biologics. As RNA and oligonucleotide therapeutics enter broader immunology indications, healthcare systems must balance innovation adoption with affordability frameworks. Patent protection also shapes competitive landscapes, influencing biosimilar development timelines and market entry barriers. Policymakers and regulators will play key roles in defining approval standards, safety surveillance expectations, and equitable access pathways for next-generation genomic medicines.
The Notice of Allowance granted to Hoth Therapeutics marks a pivotal advancement in RNA-based immunology innovation. By combining exon-skipping technology with immune signaling modulation, the company is advancing a differentiated strategy for allergic disease intervention. As gene-modulating therapies continue to reshape the therapeutic landscape, intellectual property milestones such as this will underpin future clinical development, regulatory progression, and patient-centric precision medicine breakthroughs.
Source: Hoth Therapeutics press release
